Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication used for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.
Read the full article on WikipediaMetastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) Clinical criteria: Treatment Phase: Initial treatment covering the first 3 treatment cycles The condition must be unsuitable for each of: (i) curative surgical resection, (ii) curative radiotherapy, AND Patient must have had a WHO performance status of 0 or 1, AND The treatment must be the sole PBS-subsidised therapy for this condition.
Stage IV (metastatic) non-small cell lung cancer (NSCLC) Clinical criteria: Treatment Phase: Initial treatment - 3 weekly treatment regimen Patient must not have previously been treated for this condition in the metastatic setting; OR The condition must have progressed after treatment with a prior targeted therapy PBS-listed for this condition, AND Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer, AND Patient must have a WHO performance status of 0 or 1, AND The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material, AND The treatment must not exceed a total of 7 doses under this restriction.
“Cemiplimab targets the cellular pathway known as PD-1 (protein found on the body's immune cells and some cancer cells) so it acts as a checkpoint inhibitor.”
“19 days”
Working under the parallel aged-care framework? Aged-care equivalent →